New evidence sharpens the picture on ocular FIP treatment

Ocular feline infectious peritonitis is getting a sharper clinical focus as new data begin to address a question many veterinarians have faced in practice: how well do current antivirals work when FIP involves the eye. The immediate hook is a newly surfaced prospective study of 118 cats treated with GS-441524 for FIP-related ocular manifestations, paired with a recent 2025 observational case series showing that remdesivir alone or with GS-441524 produced effective uveitis responses in 82% of 20 cats with ocular involvement. Together, those reports suggest ocular FIP is no longer being discussed only through isolated success stories, but through a growing body of structured clinical evidence. (visualize.jove.com)

That matters because FIP treatment has changed dramatically in just a few years. The 2022 AAFP/EveryCat FIP diagnosis guidelines were published at a time when effective antivirals were known from research but were not legally accessible in many markets. Since then, remdesivir and GS-441524 have been studied in effusive, neurologic, and mixed FIP presentations, with multiple reports showing high remission rates among cats that complete treatment. Clinician education updates now commonly cite overall response rates in the 85% to 90% range in practice, even as diagnosis and protocol selection remain challenging. In the U.S., FDA later announced it did not intend to enforce approval requirements for compounded GS-441524 prescribed by veterinarians for specific cats with FIP under GFI #256, opening a more formal pathway for access even though no FDA-approved feline FIP drug exists. (pmc.ncbi.nlm.nih.gov)

The ocular-specific evidence is still early, but it's becoming more actionable. The Zurich prospective study was designed to evaluate the efficacy of GS-441524 on FIP-related ocular manifestations, signaling that ophthalmic outcomes are now being examined directly rather than folded into broader survival endpoints. Meanwhile, the 2025 case series on cats with ocular involvement found associated uveitis responded effectively in 82% of cases treated with injectable remdesivir or oral GS-441524, with dosing ranges that increased when ocular disease was present. That practical emphasis lines up with recent clinician-facing summaries that frame ocular FIP as more than a secondary finding: in some cats, ocular signs are the dominant presentation, and they may be the first clue to underlying systemic disease. Reported findings include anterior chamber changes such as keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous exudate, as well as posterior segment lesions including retinal hemorrhage, vascular tortuosity, tapetal or non-tapetal lesions, retinal detachment, and perivascular cuffing. Earlier neurologic FIP work also documented serial ocular imaging as part of response assessment, and broader retrospective treatment data have found that neurologic and ocular signs resolved in nearly all surviving cats in some cohorts. (visualize.jove.com)

There are still important caveats. Much of the FIP treatment literature remains observational, and protocols vary by formulation, route, dose, and case severity. One recent study on high-dose induction and shorter treatment duration explicitly excluded cats with only ocular or neurologic signs, underscoring that these presentations may not fit simplified protocols. That same line of work has pushed the field toward more objective treatment monitoring, including serial assessment of acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, along with the albumin:globulin ratio, because early clinical improvement alone may not mean viral clearance. Expert commentary has echoed that caution. In Worms & Germs, infectious disease specialist Dr. Scott Weese noted that while shorter courses may be feasible in selected cats, he'd be more cautious in ocular or neurologic FIP, even if a patient appears to respond well. Clinician-facing summaries have also emphasized that cats with ocular and neurologic forms appear to require larger doses because treatment must penetrate the blood-ocular and blood-brain barriers as inflammation changes over time. (pubmed.ncbi.nlm.nih.gov)

Diagnosis remains another real-world challenge, even in the antiviral era. Educational updates for practitioners continue to stress that definitive diagnosis is often difficult in routine practice, so clinicians are still relying on a presumptive framework that combines signalment, history, clinicopathologic changes, imaging, effusion analysis when present, and compatible ocular or neurologic findings. That is especially relevant for ocular cases, where the eye exam may raise suspicion before classic wet FIP features are obvious.

Industry response has largely centered on access and standardization. AAHA reported that Stokes Pharmacy began offering compounded prescription GS-441524 in June 2024, and Wedgewood added a GS-441524 formulation in June 2025, giving veterinarians more options through established pharmacy channels rather than informal sourcing. That doesn't resolve every concern around consistency, cost, or evidence quality, but it does move treatment decisions closer to routine veterinary prescribing and monitoring. (aaha.org)

Why it matters: For veterinary teams, ocular FIP is where diagnosis, prognosis, and treatment intensity often intersect. Eye findings may be among the clues that push FIP higher on the differential list, but they also signal a form of disease that may need higher antiviral exposure, longer monitoring, and more nuanced conversations with pet parents about expected response. The newer literature supports real optimism, especially compared with the pre-antiviral era, but it also argues against one-size-fits-all protocols. Clinics may need to think in terms of phenotype-specific treatment plans, ophthalmic follow-up, and clearer internal guidance on when to escalate dose, extend duration, or suspect relapse. Objective markers such as serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin trends may also become more useful as practices try to decide not just whether a cat is improving, but whether treatment can safely stop. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely focus on protocol refinement, not just proof of concept, including whether ocular FIP can safely follow shorter treatment courses, which dosing strategies best protect against relapse, and how prospective ophthalmic outcome data compare across GS-441524, remdesivir, and rescue options such as molnupiravir. Just as important will be whether emerging stop-treatment criteria based on acute phase proteins and other objective markers hold up in cats with ocular or neurologic disease, since those are the patients many clinicians still view as least suited to abbreviated protocols. (pubmed.ncbi.nlm.nih.gov)